Innovent Biologics (01801) released its monthly return on movements in securities for the period ended 31 January 2026. The authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001 per share, totaling USD 50,000 in authorized capital.

The number of issued shares (excluding treasury shares) rose from 1,734,623,465 to 1,735,186,039, reflecting an increase of 562,574 shares during the month. The company confirmed that it meets the prescribed public float requirement of 25%.

Changes in share options under different incentive plans include the issuance of 53,000 new shares from the Pre-IPO Share Incentive Plan and 509,574 new shares from the Post-IPO share option scheme, with 14,600 shares from the 2024 Share Scheme having lapsed. Total funds raised from exercised options amounted to HKD 19,975,088.9. No new shares were issued under any other arrangement this month, and no treasury shares were involved in any transactions.